Annual EBIT
-$765.00 K
+$115.00 K+13.07%
December 31, 2023
Summary
- As of February 6, 2025, XTLB annual earnings before interest & taxes is -$765.00 thousand, with the most recent change of +$115.00 thousand (+13.07%) on December 31, 2023.
- During the last 3 years, XTLB annual EBIT has risen by +$183.00 thousand (+19.30%).
- XTLB annual EBIT is now -129.72% below its all-time high of $2.57 million, reached on December 31, 2009.
Performance
XTLB EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$460.00 K
+$231.00 K+33.43%
September 30, 2024
Summary
- As of February 6, 2025, XTLB quarterly earnings before interest & taxes is -$460.00 thousand, with the most recent change of +$231.00 thousand (+33.43%) on September 30, 2024.
- Over the past year, XTLB quarterly EBIT has dropped by -$961.00 thousand (-191.82%).
- XTLB quarterly EBIT is now -108.92% below its all-time high of $5.16 million, reached on December 31, 2009.
Performance
XTLB Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$2000.00
-$273.00 K-100.74%
September 30, 2024
Summary
- As of February 6, 2025, XTLB TTM earnings before interest & taxes is -$2000.00, with the most recent change of -$273.00 thousand (-100.74%) on September 30, 2024.
- Over the past year, XTLB TTM EBIT has dropped by -$632.00 thousand (-100.32%).
- XTLB TTM EBIT is now -100.04% below its all-time high of $5.33 million, reached on December 31, 2009.
Performance
XTLB TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
XTLB EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.1% | -191.8% | -100.3% |
| 3 y3 years | +19.3% | -191.8% | -100.3% |
| 5 y5 years | +3.5% | -212.2% | +99.8% |
XTLB EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.8% | -171.0% | +48.5% | -100.3% | +99.9% |
| 5 y | 5-year | at high | +25.8% | -171.0% | +59.8% | -100.3% | +99.9% |
| alltime | all time | -129.7% | +97.0% | -108.9% | +98.3% | -100.0% | +100.0% |
XTL Biopharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$460.00 K(-33.4%) | -$2000.00(-100.7%) |
| Jun 2024 | - | -$691.00 K(-237.9%) | $271.00 K(-57.0%) |
| Mar 2024 | - | $501.00 K(-22.7%) | $630.00 K(-182.4%) |
| Dec 2023 | -$765.00 K(-13.1%) | $648.00 K(-446.5%) | -$765.00 K(-55.4%) |
| Sep 2023 | - | -$187.00 K(-43.7%) | -$1.72 M(-26.9%) |
| Jun 2023 | - | -$332.00 K(-62.9%) | -$2.35 M(+2.5%) |
| Mar 2023 | - | -$894.00 K(+196.0%) | -$2.29 M(+160.1%) |
| Dec 2022 | -$880.00 K(-14.6%) | -$302.00 K(-63.1%) | -$880.00 K(+1.9%) |
| Sep 2022 | - | -$819.00 K(+198.9%) | -$864.00 K(-1516.4%) |
| Jun 2022 | - | -$274.00 K(-153.2%) | $61.00 K(-107.5%) |
| Mar 2022 | - | $515.00 K(-280.1%) | -$809.00 K(-48.0%) |
| Dec 2021 | -$1.03 M(+8.8%) | -$286.00 K(-369.8%) | -$1.56 M(+1.9%) |
| Sep 2021 | - | $106.00 K(-109.3%) | -$1.53 M(+24.9%) |
| Jun 2021 | - | -$1.14 M(+393.1%) | -$1.22 M(+22.1%) |
| Mar 2021 | - | -$232.00 K(-9.7%) | -$1.00 M(-2.4%) |
| Dec 2020 | -$948.00 K(+12.6%) | -$257.00 K(-162.7%) | -$1.03 M(+1.3%) |
| Sep 2020 | - | $410.00 K(-144.4%) | -$1.01 M(-37.5%) |
| Jun 2020 | - | -$923.00 K(+259.1%) | -$1.62 M(+80.3%) |
| Mar 2020 | - | -$257.00 K(+5.3%) | -$900.00 K(+6.9%) |
| Dec 2019 | -$842.00 K(+6.2%) | -$244.00 K(+22.6%) | -$842.00 K(+2.8%) |
| Sep 2019 | - | -$199.00 K(-0.5%) | -$819.00 K(+1.1%) |
| Jun 2019 | - | -$200.00 K(+0.5%) | -$810.00 K(-56.8%) |
| Mar 2019 | - | -$199.00 K(-10.0%) | -$1.87 M(+136.2%) |
| Dec 2018 | -$793.00 K(-36.4%) | -$221.00 K(+16.3%) | -$793.00 K(-43.0%) |
| Sep 2018 | - | -$190.00 K(-85.0%) | -$1.39 M(+57.8%) |
| Jun 2018 | - | -$1.26 M(-243.4%) | -$882.00 K(+1503.6%) |
| Mar 2018 | - | $881.00 K(-207.4%) | -$55.00 K(-95.6%) |
| Dec 2017 | -$1.25 M(-27.3%) | -$820.00 K(-356.3%) | -$1.25 M(+54.8%) |
| Sep 2017 | - | $320.00 K(-173.4%) | -$805.00 K(-42.9%) |
| Jun 2017 | - | -$436.00 K(+40.6%) | -$1.41 M(-2.1%) |
| Mar 2017 | - | -$310.00 K(-18.2%) | -$1.44 M(-15.5%) |
| Dec 2016 | -$1.71 M(-14.6%) | -$379.00 K(+33.0%) | -$1.71 M(-19.2%) |
| Sep 2016 | - | -$285.00 K(-38.8%) | -$2.11 M(-4.6%) |
| Jun 2016 | - | -$466.00 K(-19.0%) | -$2.21 M(-0.7%) |
| Mar 2016 | - | -$575.00 K(-26.6%) | -$2.23 M(+10.1%) |
| Dec 2015 | -$2.01 M(-0.7%) | -$783.00 K(+102.8%) | -$2.02 M(+5.8%) |
| Sep 2015 | - | -$386.00 K(-19.8%) | -$1.91 M(+1.0%) |
| Jun 2015 | - | -$481.00 K(+29.6%) | -$1.89 M(+5.5%) |
| Mar 2015 | - | -$371.00 K(-44.9%) | -$1.79 M(-11.0%) |
| Dec 2014 | -$2.02 M(+43.3%) | -$673.00 K(+83.4%) | -$2.02 M(+130.8%) |
| Sep 2014 | - | -$367.00 K(-4.2%) | -$873.00 K(+1547.2%) |
| Jun 2014 | - | -$383.00 K(-35.3%) | -$53.00 K(-94.2%) |
| Mar 2014 | - | -$592.00 K(-226.2%) | -$911.00 K(-35.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$1.41 M(-44.1%) | $469.00 K(+3.5%) | -$1.41 M(-56.6%) |
| Sep 2013 | - | $453.00 K(-136.5%) | -$3.25 M(-15.6%) |
| Jun 2013 | - | -$1.24 M(+13.6%) | -$3.86 M(+19.3%) |
| Mar 2013 | - | -$1.09 M(-20.5%) | -$3.23 M(+28.9%) |
| Dec 2012 | -$2.53 M(+106.9%) | -$1.37 M(+816.0%) | -$2.51 M(+70.7%) |
| Sep 2012 | - | -$150.00 K(-75.7%) | -$1.47 M(-8.6%) |
| Jun 2012 | - | -$617.00 K(+67.7%) | -$1.61 M(+26.2%) |
| Mar 2012 | - | -$368.00 K(+9.9%) | -$1.27 M(+2.7%) |
| Dec 2011 | -$1.22 M(-2.3%) | -$335.00 K(+15.9%) | -$1.24 M(+2.7%) |
| Sep 2011 | - | -$289.00 K(+2.1%) | -$1.21 M(-0.6%) |
| Jun 2011 | - | -$283.00 K(-15.3%) | -$1.22 M(-2.7%) |
| Mar 2011 | - | -$334.00 K(+10.6%) | -$1.25 M(-0.1%) |
| Dec 2010 | -$1.25 M(-148.6%) | -$302.00 K(+2.0%) | -$1.25 M(-129.7%) |
| Sep 2010 | - | -$296.00 K(-6.6%) | $4.21 M(-0.5%) |
| Jun 2010 | - | -$317.00 K(-5.4%) | $4.23 M(+26.9%) |
| Mar 2010 | - | -$335.00 K(-106.5%) | $3.34 M(-37.4%) |
| Dec 2009 | $2.57 M(-114.0%) | $5.16 M(-1982.8%) | $5.33 M(-164.2%) |
| Sep 2009 | - | -$274.00 K(-77.4%) | -$8.30 M(-10.0%) |
| Jun 2009 | - | -$1.21 M(-173.2%) | -$9.22 M(-20.8%) |
| Mar 2009 | - | $1.66 M(-119.6%) | -$11.64 M(+2.8%) |
| Dec 2008 | -$18.44 M(-28.3%) | -$8.47 M(+605.8%) | -$11.33 M(-61.6%) |
| Sep 2008 | - | -$1.20 M(-66.9%) | -$29.50 M(+5.1%) |
| Jun 2008 | - | -$3.63 M(-284.3%) | -$28.08 M(-12.4%) |
| Mar 2008 | - | $1.97 M(-107.4%) | -$32.05 M(-5.5%) |
| Dec 2007 | -$25.73 M(+60.4%) | -$26.64 M(<-9900.0%) | -$33.91 M(+43.4%) |
| Sep 2007 | - | $226.00 K(-103.0%) | -$23.65 M(-0.5%) |
| Jun 2007 | - | -$7.61 M(-6772.8%) | -$23.77 M(+19.3%) |
| Mar 2007 | - | $114.00 K(-100.7%) | -$19.91 M(0.0%) |
| Dec 2006 | -$16.05 M(+27.4%) | -$16.39 M(<-9900.0%) | -$19.91 M(+4.7%) |
| Sep 2006 | - | $114.00 K(-103.0%) | -$19.03 M(+1.0%) |
| Jun 2006 | - | -$3.75 M(-3393.0%) | -$18.84 M(+6.9%) |
| Mar 2006 | - | $114.00 K(-100.7%) | -$17.63 M(+7.2%) |
| Dec 2005 | -$12.60 M(-24.9%) | -$15.50 M(-5354.2%) | -$16.44 M(-19.0%) |
| Sep 2005 | - | $295.00 K(-111.6%) | -$20.31 M(+2.9%) |
| Jun 2005 | - | -$2.54 M(-294.8%) | -$19.74 M(-11.3%) |
| Mar 2005 | - | $1.30 M(-106.7%) | -$22.25 M(-1.9%) |
| Dec 2004 | -$16.78 M(+15.2%) | -$19.37 M(-2341.7%) | -$22.69 M(+582.3%) |
| Sep 2004 | - | $864.00 K(-117.1%) | -$3.33 M(-20.6%) |
| Jun 2004 | - | -$5.05 M(-685.0%) | -$4.19 M(-585.0%) |
| Mar 2004 | - | $864.00 K | $864.00 K |
| Dec 2003 | -$14.56 M(-17.8%) | - | - |
| Dec 2002 | -$17.71 M(+17.1%) | - | - |
| Dec 2001 | -$15.12 M | - | - |
FAQ
- What is XTL Biopharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual EBIT year-on-year change?
- What is XTL Biopharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly EBIT year-on-year change?
- What is XTL Biopharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals TTM EBIT year-on-year change?
What is XTL Biopharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of XTLB is -$765.00 K
What is the all time high annual EBIT for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual earnings before interest & taxes is $2.57 M
What is XTL Biopharmaceuticals annual EBIT year-on-year change?
Over the past year, XTLB annual earnings before interest & taxes has changed by +$115.00 K (+13.07%)
What is XTL Biopharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of XTLB is -$460.00 K
What is the all time high quarterly EBIT for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly earnings before interest & taxes is $5.16 M
What is XTL Biopharmaceuticals quarterly EBIT year-on-year change?
Over the past year, XTLB quarterly earnings before interest & taxes has changed by -$961.00 K (-191.82%)
What is XTL Biopharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of XTLB is -$2000.00
What is the all time high TTM EBIT for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high TTM earnings before interest & taxes is $5.33 M
What is XTL Biopharmaceuticals TTM EBIT year-on-year change?
Over the past year, XTLB TTM earnings before interest & taxes has changed by -$632.00 K (-100.32%)